Novel perspectives in cardio-oncology: Early MEchanisms of caRdiotoxicity and strateGiEs for adjuvaNt Therapy (EMERGENT)

Proponente Isotta Chimenti - Professore Associato
Sottosettore ERC del proponente del progetto
Componenti gruppo di ricerca
Componente Categoria
Luca D'Ambrosio Dottorando/Assegnista/Specializzando componente non strutturato del gruppo di ricerca
Elena Cavarretta Componenti strutturati del gruppo di ricerca
Sebastiano Sciarretta Componenti strutturati del gruppo di ricerca
Componente Qualifica Struttura Categoria
Francesca Pagano Ricercatore IBBC-CNR Altro personale aggregato Sapienza o esterni, titolari di borse di studio di ricerca
Susana Constantino Santos Professore Centro Cardiovascular da Universidade de Lisboa Altro personale aggregato Sapienza o esterni, titolari di borse di studio di ricerca

Most breast cancer (BC) patients undergo radiotherapy (RT) as part of their treatment. Left BC-RT inevitably leads to coincidental irradiation of the heart, resulting in a bystander cardiotoxic effect. In fact, these patients face an increased long-term risk of several kinds of heart diseases, including ischemic heart disease and congestive heart failure. The mechanisms involved in cardiotoxicity at therapeutic radiation doses, though, are still largely unknown. Evidence indicates a role for radiation-induced vascular injury, leading to inflammatory and thrombotic events, focal ischemia, and interstitial fibrosis. The involvement of cardiac stromal cells (CSCs) in these pathogenetic events is still to be elucidated.
The present project proposal is based on the hypothesis that fibrotic polarization of CSCs mediates early mechanisms of cardiotoxicity, and that retrieval of a beneficial phenotype may be protective against cardiac side effects of RT. EMERGENT will exploit a clinically relevant model of chest irradiation in adult female rats, with highly optimized heart dosimetry, with late onset cardiac dysfunction. EMERGENT aims at: 1) elucidating the features of CSC functional phenotype and pro-fibrotic polarization from early stages of RT cardiotoxicity before impairment of cardiac function, and 2) establishing a proof-of-concept adjuvant therapy during RT mediated by an anti-fibrotic effect on CSCs. The expected results of EMERGENT will provide a novel protective strategy for BC-RT patients to prevent cardiotoxicity, thus possibly reducing the late incidence of cardiovascular complications and increasing the overall long-term survival of BC survivors.

LS3_8, LS4_7, LS4_1

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma